Email this article EFFICIENCY OF TARGETED THERAPY USED IN THE HETEROGENEOUS POPULATION OF PATIENTS WITH METASTATIC KIDNEY CANCER
- Authors: Alekseev B.Y.1,2, Kalpinsky A.S.1,2
-
Affiliations:
- P.A. Herzen Moscow Oncology Research Institute
- Department of Urology with a Course of Oncourology, Faculty of Advanced Training, People’s Friendship University of Russia, Moscow
- Issue: Vol 8, No 3 (2012)
- Pages: 37-42
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.09.2012
- URL: https://oncourology.abvpress.ru/oncur/article/view/316
- DOI: https://doi.org/10.17650/1726-9776-2012-8-3-37-42
- ID: 316
Cite item
Full Text
Abstract
Most clinical trials were conducted on a thoroughly selected population of patients with mainly clear-cell metastatic renal-cell carcinoma (mRCC) without brain metastases and with a good somatic status. In routine clinical practice, the population of patients with mRCC is more heterogeneous: there are patients who have, in addition to the most common clear-cell mRCC, non-clear-cell mRCC, brain metastases and a somatic ECOG score of > 1. Undoubtedly, practitioners have a concern in the efficiency, tolerance, and expediency of using target drugs in all groups of patients with mRCC. This review gives a number of drugs approved for the treatment of mRCC and analyzes criteria for their choice.
About the authors
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research Institute; Department of Urology with a Course of Oncourology,Faculty of Advanced Training, People’s Friendship University of Russia, Moscow
Author for correspondence.
Email: byalekseev@mail.ru
Russian Federation
A. S. Kalpinsky
P.A. Herzen Moscow Oncology Research Institute; Department of Urology with a Course of Oncourology,Faculty of Advanced Training, People’s Friendship University of Russia, Moscow
Email: byalekseev@mail.ru
Russian Federation
References
Supplementary files
